Compare LGND & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGND | AMRX |
|---|---|---|
| Founded | 1987 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.4B |
| IPO Year | 1997 | 2018 |
| Metric | LGND | AMRX |
|---|---|---|
| Price | $307.47 | $20.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $344.25 | $22.71 |
| AVG Volume (30 Days) | 195.5K | ★ 2.6M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2886.36 | 157.89 |
| EPS | ★ 1.63 | 0.37 |
| Revenue | ★ $141,102,000.00 | N/A |
| Revenue This Year | $8.04 | $4.53 |
| Revenue Next Year | $31.71 | $9.13 |
| P/E Ratio | $189.15 | ★ $53.61 |
| Revenue Growth | ★ 29.48 | N/A |
| 52 Week Low | $175.89 | $9.99 |
| 52 Week High | $326.63 | $21.18 |
| Indicator | LGND | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.77 | 59.27 |
| Support Level | $277.97 | $16.59 |
| Resistance Level | $315.53 | $20.98 |
| Average True Range (ATR) | 10.35 | 0.62 |
| MACD | -0.11 | -0.08 |
| Stochastic Oscillator | 78.61 | 73.83 |
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.